Dogwood Therapeutics, Inc.
NASDAQ: DWTX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Gregory Duncan
- Employees
- 12
- Headquarters
- Alpharetta, United States
- IPO year
- 2020
- Market cap
- $2.9M
- Website
- https://www.dwtx.com
Loading DWTX…
Loading profile data…Frequently asked questions about DWTX
What does Dogwood Therapeutics, Inc. (DWTX) do?
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineere...
Where does DWTX trade?
Dogwood Therapeutics, Inc. (DWTX) trades on the NASDAQ Capital Market.
What sector is DWTX in?
Dogwood Therapeutics, Inc. (DWTX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Dogwood Therapeutics, Inc.?
Gregory Duncan is the chief executive officer of Dogwood Therapeutics, Inc. (DWTX).
Where is Dogwood Therapeutics, Inc. headquartered?
Dogwood Therapeutics, Inc. is headquartered in United States.
Does DWTX pay a dividend?
Dogwood Therapeutics, Inc. (DWTX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did DWTX go public?
Dogwood Therapeutics, Inc. (DWTX) completed its initial public offering in 2020.